Patent · US Active

Oxprenolol compositions for treating cancer

US10828270B2 · kind B2 · utility

1Cited by

1References

16Claims

0Family size

Assignee

ACTIMED THERAPEUTICS LIMITED · GB

Inventors

Andrew J. S. Coats · Melbourne, AU
Stefan Anker · Berlin, DE
Jochen Springer · Falkensee, DE

Key dates

Filing date	Mar 16, 2018
Grant date	Nov 10, 2020
Priority date	—
Expiry date	Mar 16, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.